Magnolol-Coumarin-Phenylbutyric acid Conjugates: An Anticancer Prodrug via multiple targets

6Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present here, the design and synthesis of a phenylbutyric acid-magnolol-coumarin conjugates (5). Compound 5 is a multifunctional molecule composed of magnolol, coumarin, phenylbutyric acid as model active drugs via ester. Upon entering tumor cells, ester bond cleavage occurs as well as active drug magnolol, coumarin and phenylbutyric acid release to attack cancer cells. In vitro anti-proliferation experiments showed that the inhibitory activity of compound 5 against HepG2, MCF-7, A431 and A549 cells was significantly higher than that of its single parent compound. Moreover, compound 5 had a long-term effect. Due to fluorescence of compound 5, it can serve as a fluorescence imaging agent and its uptake can be monitored. Compound 5 may provide a reference for the design of new derivatives of magnolol.

Cite

CITATION STYLE

APA

Tao, A., Song, Z., Feng, X., Hu, B., & Lei, X. (2019). Magnolol-Coumarin-Phenylbutyric acid Conjugates: An Anticancer Prodrug via multiple targets. In IOP Conference Series: Earth and Environmental Science (Vol. 330). Institute of Physics Publishing. https://doi.org/10.1088/1755-1315/330/4/042054

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free